Explore a selection of our essential drug information below, or:
Identification
- Summary
Isoxsuprine is a beta-adrenergic agonist used in the symptomatic treatment of cerebrovascular insufficiency, peripheral vascular disease of arteriosclerosis obliterans, thromboangiitis obliterans (Buerger's disease) and Raynaud's disease.
- Generic Name
- Isoxsuprine
- DrugBank Accession Number
- DB08941
- Background
A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Isoxsuprine (DB08941)
- Weight
- Average: 301.386
Monoisotopic: 301.167793605 - Chemical Formula
- C18H23NO3
- Synonyms
- Isoxsuprine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Arteriosclerosis obliterans ••• ••••• •••••• Treatment of Buerger's disease ••• ••••• •••••• Treatment of Cerebrovascular insufficiency ••• ••••• •••••• Treatment of Raynaud's phenomenon ••• ••••• •••••• Treatment of Thromboangiitis obliterans ••• ••••• •••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide The risk or severity of adverse effects can be increased when Abaloparatide is combined with Isoxsuprine. Acebutolol The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Isoxsuprine. Acemetacin The risk or severity of hypertension can be increased when Isoxsuprine is combined with Acemetacin. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Isoxsuprine. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Isoxsuprine hydrochloride V74TEQ36CO 579-56-6 QVPSGVSNYPRFAS-BQZDIUEZSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral Syntho Pharmaceuticals Inc. 2020-06-11 Not applicable US 
Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral BI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY 2011-06-02 Not applicable US Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral Eci Pharmaceuticals Llc 2011-06-02 2024-09-30 US Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral Bi-Coastal Pharmaceutical Corporation 2011-06-02 Not applicable US Isoxsuprine Hydrochloride Tablet 10 mg/1 Oral Syntho Pharmaceuticals Inc. 2020-02-06 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (10 mg/1) Tablet Oral Syntho Pharmaceuticals Inc. 2020-02-06 Not applicable US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (10 mg/1) Tablet Oral Eci Pharmaceuticals Llc 2011-06-02 2024-09-30 US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (20 mg/1) Tablet Oral Vista Pharmaceuticals, Inc. 1997-09-19 Not applicable US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (10 mg/1) Tablet Oral Bi-Coastal Pharmaceutical Corporation 2011-06-02 Not applicable US Isoxsuprine Hydrochloride Isoxsuprine hydrochloride (20 mg/1) Tablet Oral BI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY 2011-06-02 Not applicable US
Categories
- ATC Codes
- C04AA01 — Isoxsuprine
- Drug Categories
- 2-Amino-1-Phenylethanol Derivatives
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Agents producing tachycardia
- Agents that produce hypertension
- Alcohols
- Amines
- Amino Alcohols
- Autonomic Agents
- Cardiovascular Agents
- Ethylamines
- Hypotensive Agents
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Peripheral Vasodilators
- Phenethylamines
- Propanolamines
- Propanols
- Reproductive Control Agents
- Sympathomimetics
- Tocolytic Agents
- Vasodilating Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenylpropanes
- Direct Parent
- Phenylpropanes
- Alternative Parents
- Phenoxy compounds / Phenol ethers / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- 1,2-aminoalcohol / 1-hydroxy-2-unsubstituted benzenoid / Alcohol / Alkyl aryl ether / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Ether / Hydrocarbon derivative
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R15UI3245N
- CAS number
- 395-28-8
- InChI Key
- BMUKKTUHUDJSNZ-HBUWYVDXSA-N
- InChI
- InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3/t13-,14-,18-/m1/s1
- IUPAC Name
- 4-[(1S,2R)-1-hydroxy-2-{[(2R)-1-phenoxypropan-2-yl]amino}propyl]phenol
- SMILES
- C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 11779629
- PubChem Substance
- 310264908
- ChemSpider
- 9954311
- 6066
- ZINC
- ZINC000009302317
- Wikipedia
- Isoxsuprine
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1, 2 Completed Treatment Multiple Sclerosis 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection 5 MG/ML Tablet Oral 10 mg/1 Tablet Oral 20 mg/1 Injection Tablet Oral 20 MG Tablet Oral 10 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0507 mg/mL ALOGPS logP 2.06 ALOGPS logP 2.56 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 9.65 Chemaxon pKa (Strongest Basic) 9 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 61.72 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 86.64 m3·mol-1 Chemaxon Polarizability 34.12 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-00di-4910000000-8cd52222fedb84b3cd54 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-003u-0942000000-8922892983d007d6d065 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0bu9-3940000000-a278f0d2886c8788b7d8 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0016-8940000000-5d32b1e6973ccf760747 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-004l-2910000000-c59deec82a2be68b520d Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-004j-8921000000-a3660049c006141ac018 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9510000000-73025659f0951e8cbf43 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 174.71597 predictedDeepCCS 1.0 (2019) [M+H]+ 177.07397 predictedDeepCCS 1.0 (2019) [M+Na]+ 183.9558 predictedDeepCCS 1.0 (2019)
Drug created at May 26, 2014 21:29 / Updated at February 21, 2021 18:52